US FDA staff flags concerns about Geron's anemia treatment

Geron

12/03/2024 13:38

March 12 (Reuters) - The U.S. health regulator's staff
on Tuesday flagged concerns that the late-stage trial data on
Geron's  GERN.O  anemia drug does not show whether the risks of
treatment with imetelstat are outweighed by the potential
benefit, documents released ahead of a meeting of independent
experts showed.
    

 (Reporting by Christy Santhosh and Pratik Jain in Bengaluru;
Editing by Shailesh Kuber)
 ((Christy.Santhosh@thomsonreuters.com;))